

Lexington, Kentucky, USA

Formulation Development & Manufacturing of Sterile Injectables

Established in 2007, Piramal's Lexington site provides sterile compounding, fill/finish and lyophilization capabilities for sterile injectable drug products. The site is fully self-sufficient, with in-house analytical, microbiological, formulation development, and manufacturing services that support customer needs from preclinical to clinical and commercial. Lexington boasts a rich history of expertise across the complexity scale, from simple formulations such as liquid and lyophilization solutions to complex drugs like ADCs and nanoparticle suspensions.



Site Capabilities – Development Services

- Formulation Development
 - Liquid products (solutions and suspensions)
 - Lyophilized products (aqueous and non-aqueous)
- Analytical Methods Development
 - Variety of analytical techniques and instrumentation to support cGMP manufacturing of clinical and commercial products
- Microbiological Methods Development
 - Full-service microbiology lab on site with wide range of services
- Lyophilization Development
 - Shelf loading configurations to account for different radiant heat transfer
 - Ability to leverage in-process sampling and pressure rise to determine sublimation rates and residual moisture levels
 - Historical record of sublimation rates to transition step durations within given cycles
 - Lyophilization cycle development based on fundamental thermal properties of each individual solution

Site Capabilities – Manufacturing

- 22,000 square foot manufacturing facility
- 100% isolator based fill/finish technology
- Sterile and non-sterile compounding
- Vial capabilities from 2ml to 100ml for liquid products
- Vial capabilities from 2ml to 50ml for lyophilized products
- Full cold chain, gas overlay, and light protection capabilities

Site Capabilities – Potent Compounds

- Able to handle highly potent drugs: cytotoxics, steroids, acutely toxic compounds
- Standard Operating Procedure (SOP) detailing a process for the assessment of the potency of each compound being handled
- Occupational Exposure Limit (OEL) is determined for each compound by a certified third-party toxicologist
- Mobile isolator technology provides a physical barrier that protects staff from toxic substances and encloses products in a Grade A Environment
- Similar fixed isolators used in the development labs to mimic manufacturing operations and enable formulation and analytical development on toxic substances

Site Capabilities – Liposomal Formulations

- Experienced in complex multi-step/multi-day formulations
- In-process testing to ensure proper particle size, concentration, absence of endotoxin
- Small (<50L) to large (>500L) batch size capabilities
- Capability to run extended campaign-style batches on commercial grade Steriline Filling Line
- Multiple clinical and late phase projects completed
- Technology expertise: large scale extrusion, microfluidization, tangential flow filtration (TFF), rotary evaporation, complex filtration

Regulatory Approvals






ADCelerate

Rapid, Integrated ADC to IND

ADCelerate is Piramal Pharma Solutions' rapid approach to delivering Phase-I appropriate ADC drug substance and drug product, so that you can accelerate the delivery of your product to patients in the clinic.



OUR GLOBAL PRESENCE



*Yapan Bio: A Piramal Pharma Ltd. Associate Company



Get in touch with us
contact.us@piramal.com
www.piramalpharmasolutions.com

